Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

No association between MDM2 SNP309 promoter polymorphism and basal cell carcinoma of the skin.

The British journal of dermatology - 1 Aug 2007

Wilkening S, Hemminki K, Rudnai P, Gurzau E, Koppova K, Försti A, Kumar R

Abstract excerpt

BACKGROUND: The MDM2 oncoprotein promotes cell survival and cell cycle progression by inhibiting the p53 tumour suppressor protein. Further, overexpression of the MDM2 gene can inhibit DNA double-strand break repair in a p53-independent manner. Recent studies have shown that a single nucleotide polymorphism (SNP) in the intronic promoter region of MDM2 (called SNP309) can significantly change the expression of...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Age Factors
Share to Age of Onset
Share to Aged, 80 and over

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Carcinoma, Basal Cell

Share to DNA, Neoplasm

Share to Promoter Regions, Genetic

Share to Proto-Oncogene Proteins c-mdm2

Share to Skin Neoplasms

Source

Identifiers

PMID: 17553029
DOI: 10.1111/j.1365-2133.2007.07994.x

Genes

MDM2

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

No association between MDM2 SNP309 promoter polymorphism and basal cell carcinoma of the skin.PMID 17553029Read ↗

Association between MDM2 SNP309 and skin cancer: A meta-analysis of case-control studies.Semantic proximity Read ↗

Investigation of the effect of MDM2 SNP309 and TP53 Arg72Pro polymorphisms on the age of onset of cutaneous melanoma.Semantic proximity Read ↗

MDM2 SNP309 and p53 Arg72Pro in cutaneous melanoma: association between SNP309 GG genotype and tumor Breslow thickness.Semantic proximity Read ↗

A functional SNP in the MDM2 promoter, pigmentary phenotypes, and risk of skin cancer.Semantic proximity Read ↗

MDM2 SNP309 does not confer an increased risk to oral squamous cell carcinoma but may modulate the age of disease onset.Semantic proximity Read ↗

Contrasting effects of an Mdm2 functional polymorphism on tumor phenotypes.Semantic proximity Read ↗

Influence of the MDM2 single nucleotide polymorphism SNP309 on tumour development in BRCA1 mutation carriers.Semantic proximity Read ↗

Lack of association between the MDM2-SNP309 polymorphism and breast cancer risk.Semantic proximity Read ↗

Polymorphisms in the MDM2 promoter and risk of breast cancer: a case-control analysis in a Chinese population.Semantic proximity Read ↗

Association of MDM2 SNP309, age of onset, and gender in cutaneous melanoma.Semantic proximity Read ↗

Environment, phenotype and genetics: risk factors associated with BCC of the skin.Semantic proximity Read ↗

Results based on 124 cases of breast cancer and 97 controls from Taiwan suggest that the single nucleotide polymorphism (SNP309) in the MDM2 gene promoter is associated with earlier onset and increased risk of breast cancer.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.